126 results on '"Stadtmauer, E. A."'
Search Results
2. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder
3. Classifying ultra-high risk smoldering myeloma
4. Third consensus on medical treatment of metastatic breast cancer
5. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
6. Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study
7. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
8. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
9. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
10. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
11. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
12. Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients
13. Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder
14. Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells)
15. EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two-Arm Prospective Trial
16. Second consensus on medical treatment of metastatic breast cancer
17. Treatment of PTLD with Rituximab or Chemotherapy
18. PS1375 UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
19. Myeloid derived suppressor cells (MDSCS) reduce the manufacturing feasibilty of gene modified T cells.
20. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment
21. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
22. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib:A multicenter international myeloma working group study
23. Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
24. Classifying ultra-high risk smoldering myeloma
25. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
26. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
27. Defining The Optimal Threshold Of Peripheral Blood (PB) CD34+Cells To Initiate Apheresis In Patients With NHL Undergoing Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) After G-CSF Mobilization
28. Prophylactic Administration Of Ex VIVO Co-Stimulated Donor Lymphocyte Infusion (DLI) From Related And Unrelated Donors After Reduced Intensity Conditioning For High Risk Hematologic Malignancies
29. 315: Similar Survival after Sibling vs Unrelated Donor Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning
30. 251: Low rates of chimerism occur when alemtuzumab is added to conditioning therapy for non-myeloablative allogeneic stem cell transplantation
31. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
32. Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.
33. Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.
34. Hematologic Profiles in the Phase 3 APEX Trial.
35. Myeloablative vs non-myeloablative conditioning with allogeneic stem cell transplantation for high risk non-Hodgkin’s lymphoma: Similar outcomes despite differences in disease risk
36. Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.
37. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the phase III sprint trial of intercept pathogen inactivated platelets
38. Infectious Complications the Year after Autologous Bone Marrow Transplantation or Peripheral Stem Cell Transplantation for Treatment of Breast Cancer
39. Bone marrow purging with oligodeoxynucleotides [letter; comment]
40. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
41. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
42. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer.
43. Defining The Optimal Threshold Of Peripheral Blood (PB) CD34 + Cells To Initiate Apheresis In Patients With NHL Undergoing Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) After G-CSF Mobilization
44. A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT)
45. Similar Survival after Sibling vs Unrelated Donor Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning
46. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
47. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
48. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
49. Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.
50. Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.